Engineered cell and use thereof

By expressing cell surface molecules and XCL1/Fc that specifically recognize antigens on cells, the problem that cell therapy in the prior art is difficult to transport to tumor sites in solid tumor treatment, and significantly improves the killing activity and therapeutic effect on tumors. .

WO2024239143A1PCT designated stage expired Publication Date: 2024-11-28HONGKONG BIOHENG BIOTECH LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/095270
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing cell therapies are difficult to effectively transport the modified cells to the tumor site when treating solid tumors, resulting in poor anti-tumor effects and ineffective resistance to the immunosuppressive tumor microenvironment.

Method used

Develop an engineered cell that expresses cell surface molecules that specifically recognize antigens and exogenous XCL1 and Fc, which enhances the ability of cells to recognize and kill tumors.

Benefits of technology

By expressing cell surface molecules and XCL1/Fc that specifically recognize antigens, the killing activity and immune response of engineered cells to target cells is significantly improved, and the therapeutic effect on tumors is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023095270_28112024_PF_FP_ABST
    Figure CN2023095270_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an engineered cell, which expresses a cell surface molecule specifically recognizing an antigen and exogenous XCL1 and Fc. The present invention also provides the use of the engineered cell in treatment of diseases such as cancers, infections or autoimmune diseases. Compared with traditional engineered cells, the engineered cell of the present invention has significantly improved tumor killing activity.
Need to check novelty before this filing date? Find Prior Art

Description

Engineered cells and their uses Technical Field

[0001] The present invention belongs to the field of immunotherapy. More specifically, the present invention relates to an engineered cell that expresses cell surface molecules that specifically recognize antigens and exogenous XCL1 and Fc, and also relates to the use of the engineered cell in treating diseases such as cancer, infection or autoimmunity. Background Art

[0002] In recent years, adoptive cell therapy, as an emerging immunotherapy, has shown great advantages in the field of tumor treatment. This therapy usually requires the cells to be modified first, for example, through gene editing and / or transduction techniques to transform the cells into cells carrying exogenous proteins such as chimeric antigen receptors and T cell receptors, and then amplified in vitro and returned to the patient. At present, these therapies have shown good efficacy for hematological tumors, but their efficacy for solid tumors is still unsatisfactory. One of the reasons is that the modified cells cannot be effectively transported to the tumor site (i.e., the immunosuppressive tumor microenvironment).

[0003] Therefore, there is still a need for improved cell therapies that can counteract the inhibitory effects of the tumor microenvironment and recruit other immune effector cells to the tumor site to enhance the anti-tumor effect.

[0004] Summary of the Invention

[0005] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0006] I. Engineered Cells

[0007] In a first aspect, the present invention provides a novel engineered cell that expresses cell surface molecules that specifically recognize antigens as well as exogenous XCL1 and Fc.

[0008] a. Cell surface molecules that specifically recognize antigens

[0009] The term "cell surface molecule that specifically recognizes an antigen" refers to a molecule that is expressed on the cell surface and that is capable of specifically binding to a target molecule (e.g., an antigen). Such surface molecules generally include an antigen binding domain that can specifically bind to an antigen, a transmembrane domain that anchors the surface molecule to the cell surface, and an intracellular domain responsible for signal transmission. Examples of common such surface molecules include chimeric antigen receptors (CARs), T cell receptors (TCRs), T cell receptor fusion proteins (TFPs), T cell antigen couplers (TACs), or immune mobilization monoclonal T cell receptors (ImmTACs), etc., preferably chimeric antigen receptors or T cell receptors, more preferably chimeric antigen receptors.

[0010] The term "chimeric antigen receptor" or "CAR" refers to an artificially constructed hybrid polypeptide that generally includes an antigen (e.g., tumor antigen) binding domain (e.g., a ligand for an antibody or antigen), a transmembrane domain, a primary signaling domain, and an optional costimulatory domain, with each domain connected by a linker. CAR is capable of redirecting the specificity and reactivity of T cells and other immune cells to a selected target in a non-MHC restricted manner. In some embodiments, the functional exogenous receptor of the present invention is a chimeric antigen receptor comprising a tumor antigen binding domain, a transmembrane domain, a primary signaling domain, and optionally one or more costimulatory domains. In some embodiments, the chimeric antigen receptor further comprises one or more of the following structures: a signal peptide, a hinge region, a suicide gene, a switch structure, and the like.

[0011] The term "T cell receptor" or "TCR" refers to a membrane protein complex that responds to antigen presentation and participates in T cell activation. Stimulation of the TCR is triggered by major histocompatibility complex molecules (MHC) on antigen-presenting cells, which present antigenic peptides to T cells and bind to the TCR complex to induce a series of intracellular signaling. The TCR consists of six peptide chains that form heterodimers, which are generally divided into αβ type and γδ type. Each peptide chain includes a constant region and a variable region, wherein the variable region is responsible for binding to a specific antigen and MHC molecule. The variable region of the TCR may include an antigen binding domain or be operably connected to an antigen binding domain, wherein the definition of the antigen binding domain is as described below.

[0012] The term "T cell antigen coupler" or "TAC" includes three functional domains: (1) a tumor targeting domain, which can be a single-chain antibody, a designed ankyrin repeat protein (DARPin), or other targeting moieties; (2) an extracellular domain, which is a single-chain antibody that binds to CD3, thereby bringing the TAC receptor into proximity with the TCR receptor; and (3) a transmembrane domain and an intracellular domain of the CD4 co-receptor, which is linked to the protein kinase LCK and catalyzes the phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) of the TCR complex as the initial step in T cell activation.

[0013] The term "T cell receptor fusion protein" or "TFP" refers to a recombinant polypeptide derived from various components of a TCR, typically consisting of a TCR subunit and an antigen-binding domain attached thereto, and expressed on the cell surface. The TCR subunit includes at least part of the TCR extracellular domain, the transmembrane domain, and the TCR intracellular signaling domain.

[0014] The term "immune mobilizing monoclonal T cell receptor" or "ImmTAC" is composed of an engineered T cell receptor (TCR) and an anti-CD3 scFv, wherein: the engineered TCR can specifically recognize and bind to the HLA-peptide complex on the surface of tumor cells with significantly improved affinity, and promote T cell-mediated effector function through the interaction of the scFv antibody fragment with CD3.

[0015] In some embodiments, the cell surface molecule comprises an extracellular domain that specifically recognizes an antigen (e.g., a tumor antigen). In some embodiments, the extracellular domain comprises an antibody that specifically binds to an antigen or a ligand for the antigen. In some embodiments, the antigen is selected from the group consisting of ALK, ADRB3, AKAP-4, APRIL, ASGPR1, BCMA, B7H3, B7H4, B7H6, bcr-abl, BORIS, BST2, BAFF-R, BTLA, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD24, CD25, CD28, CD30, CD33, CD38, CD40, CD44, CD44v6, CD44v7 / 8, CD47, CD52, CD56, CD57, CD58, CD70, CD72, CD79a, CD79b, CD80, CD81, CD86, CD97, CD123, CD133, CD137, CD 138, CD151, CD171, CD179a, CD300LF, CDH16, CSPG4, CS1, Claudin6, Claudin18.1, Claudin 18.2, CEA, CEACAM6, CLL1, c-Met, CAIX, CXORF61, CA125, CYP1B1, CS1, ELF2M, EGFR, EPCAM, EGFRvIII, EphA2, ERG / TMPRSS2ETS fusion gene, ETV6-AML, EMR2, EGP2,EGP40, FAP, FAR, FBP, FLT3, FOSL1, FCRL5, FCAR, Flt3, Flt4, Frizzled, GD2, GD3, gp100, gp130, GM3, GPC2, GPC3, GPRC5D, GPR20, GloboH, GHRHR, GHR, GITR, Her2, HER3, HER-4, HMWMAA, HAVCR1, HPV E6,E7, HVEM, HIV-1Gag, HLA-A1, HLA-A2, IL6R, IL-11Ra, IL-13Ra, IGF-I receptor, LTPR, LIFRP, LRP5, IGLL1, IGF1R, KIT, Kappa Light Chain, KDR, LewisY, LMP2, LY6K, LAGE-1a, legumain, LCK, LAIR1, LILRA2, LY75, MSLN, MUC1, MUC16, MAGE-A1, MAGE3, MAD-CT-1, MelanA / MART1, ML-IAP, MYCN, mut hsp70-2, NCAM, NY-BR-1, NY-ESO-1, NA17, Notch-1-4, nAchR, NKG2D, NKG2D ligand, OY-TES1, OR51E2, OX40, PRSS21, PSCA, PD1, PD-L1, PD-L2, PSMA, Prostase, PAP, PDGFR-β, PCTA-1 / galectin 8, p53, p53 mutant, prostein, PLAC1, PANX3, PAX3, PAX5, PTCH1, RANK, RAGE-1, ROR1, Ras mutant, RhoC, RU1, RU2, Robol, SSEA-4, SSX2, SART3, Sp17, TSHR, Tn Ag, TGS5, TEM1 / CD248, TEM7R, TARP, TCRα, TCRβ, TGFBR1, TGFBR2, TNFRSF4, TWEAK-R, TLR7, TLR9, TAG72, TROP-2, Tie 2, TRP-2, TNFR1, TNFR2, TEM1, UPK2 VEGFR, WT1, XAGE1, 5T4, 8H9, αvβ6 integrin, CA9, folate receptor α, ephrin B2, tyrosinase, fucosyl GM1, o-acetyl-GD2, folate receptor β, polysialic acid, sperm protein 17, survivin and telomerase, sarcoma translocation breakpoints, human telomerase / hTERT, androgen receptor, intestinal carboxylesterase, cyclin B1, fibronectin, tenascin, oncofetal variants of tumor necrosis, and any combination thereof. Preferably,The antigen is selected from CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CD171, MUC1, MSLN, AFP, folate receptor α, CEA, PSCA, PSMA, Her2, EGFR, IL-13Ra, GD2, NKG2D, Claudin 18.2, ROR1, EGFRvIII, CS1, BCMA and GPRC5D, more preferably selected from CD19, Claudin 18.2, MSLN, GPRC5D, ROR1, CD7 and BCMA.

[0016] In some embodiments, the functional exogenous receptor comprises an extracellular domain that specifically recognizes CD19, such as an antibody targeting CD19. Antibodies targeting CD19 known in the art can be used in the present invention. In some embodiments, the antibody targeting CD19 comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-H, CDR2-H, and CDR3-H contained in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H contained in SEQ ID NO: 10 or 19; wherein the CDR1-L, CDR2-L, and CDR3-L contained in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L contained in SEQ ID NO: 11 or 20. In some embodiments, the heavy chain variable region comprises a CDR1-H as set forth in SEQ ID NO: 4, a CDR2-H as set forth in SEQ ID NO: 5, and a CDR3-H as set forth in SEQ ID NO: 6, and the light chain variable region comprises a CDR1-L as set forth in SEQ ID NO: 7, a CDR2-L as set forth in SEQ ID NO: 8, and a CDR3-L as set forth in SEQ ID NO: 9. In some embodiments, the heavy chain variable region comprises a CDR1-H as set forth in SEQ ID NO: 13, a CDR2-H as set forth in SEQ ID NO: 14, and a CDR3-H as set forth in SEQ ID NO: 15, and the light chain variable region comprises a CDR1-L as set forth in SEQ ID NO: 16, a CDR2-L as set forth in SEQ ID NO: 17, and a CDR3-L as set forth in SEQ ID NO: 18.

[0017] In some embodiments, the antibody targeting CD19 comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 10 or 19, and the light chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 11 or 20. Preferably, the antibody targeting CD19 of the present invention comprises a heavy chain variable region as set forth in SEQ ID NO: 10 and a light chain variable region as set forth in SEQ ID NO: 11, or comprises a heavy chain variable region as set forth in SEQ ID NO: 19 and a light chain variable region as set forth in SEQ ID NO: 20.

[0018] In some embodiments, the antibody targeting CD19 is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 12 or 21. Preferably, the antibody targeting CD19 is as shown in SEQ ID NO: 12 or 21.

[0019] In some embodiments, the functional exogenous receptor comprises an extracellular domain that specifically recognizes Claudin 18.2, such as an antibody targeting Claudin 18.2. Antibodies targeting Claudin 18.2 known in the art can be used in the present invention. In some embodiments, the antibody targeting Claudin 18.2 comprises a VHH, wherein the CDR1, CDR2, and CDR3 comprised by the VHH are identical to the CDR1, CDR2, and CDR3 comprised by SEQ ID NO: 25. In some embodiments, the CDR1 comprised by the VHH is as shown in SEQ ID NO: 22, the CDR2 is as shown in SEQ ID NO: 23, and the CDR3 is as shown in SEQ ID NO: 24.

[0020] In some embodiments, the antibody targeting Claudin 18.2 comprises an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 25. Preferably, the antibody targeting Claudin 18.2 of the present invention comprises the amino acid sequence shown in SEQ ID NO: 25.

[0021] In some embodiments, the functional exogenous receptor of the present invention is a chimeric antigen receptor comprising an antigen binding domain, a transmembrane domain, a primary signaling domain, and optionally one or more costimulatory domains. In some embodiments, the functional exogenous receptor of the present invention is a chimeric antigen receptor that targets CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CD171, MUC1, MSLN, AFP, folate receptor α, CEA, PSCA, PSMA, Her2, EGFR, IL-13Ra, GD2, NKG2D, Claudin 18.2, ROR1, EGFRvIII, CS1, BCMA, GPRC5D, or any combination thereof, more preferably targeting CD19, Claudin 18.2, MSLN, ROR1, GPRC5D, CD7, BCMA, or any combination thereof. In some embodiments, the chimeric antigen receptor further comprises a signal peptide and / or a hinge region.

[0022] The term "antigen-binding domain" refers to any structure (such as an antibody, etc.) or a functional variant thereof that can bind to an antigen.

[0023] In some embodiments, the antigen binding domain in the present invention is selected from an antibody. The term "antibody" has the broadest meaning understood by those skilled in the art, and includes complete antibodies such as monoclonal antibodies, polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments or synthetic polypeptides carrying one or more CDR sequences that can exhibit desired biological activity, which can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, etc.) or subclass (e.g., IgG1, IgG2, IgG2a, IgG3, IgG4, IgA1, IgA2, etc.). The term "antibody fragment" refers to at least a portion of a complete antibody or a variant thereof, and refers to a binding domain (e.g., an antigen variable region of a complete antibody) sufficient to confer recognition and specific binding to a target (e.g., an antigen) on the antibody fragment. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fd fragment, Fd', Fv fragment, scFv, disulfide-linked Fv (sdFv), linear antibodies, "diabodies" with two antigen-binding sites, single-domain antibodies (sdAb) (e.g., the heavy chain variable region VH, the light chain variable region VL, nanobodies VHH, etc. of an antibody).

[0024] In some embodiments, the antigen-binding domain of the present invention is selected from ligands, receptors, and functional fragments thereof (i.e., functional fragments with antigen-binding ability, such as extracellular domains). The term "ligand or receptor" refers to any molecule or atom capable of interacting with an antigen after binding. A ligand or receptor can be a naturally occurring molecule, such as an organic or inorganic molecule, or a synthetic molecule.

[0025] Unless the context clearly indicates otherwise, the "antigen binding domain" of the present invention encompasses antibodies, ligands, receptors, and functional fragments thereof as described above. Therefore, the antigen binding domain described in the present invention is selected from the group consisting of intact antibodies, Fab, Fab', F(ab')2, Fd fragments, Fd', Fv fragments, scFv, sdFv, linear antibodies, diabodies, sdAbs, functional fragments of ligands or receptors.

[0026] The term "functional variant" or "functional fragment" refers to a variant or fragment that contains at least one amino acid modification (i.e., substitution, deletion, or insertion) compared to the parent amino acid sequence but retains the biological activity of the parent amino acid sequence. For example, a functional fragment of a ligand or receptor in the present invention generally refers to a fragment of the ligand or receptor that is capable of binding to the corresponding immunosuppressive protein, such as the extracellular domain.

[0027] The term "heavy chain" refers to the larger of the two types of polypeptide chains found in naturally occurring conformations in antibody molecules and generally determines the class to which the antibody belongs. The term "light chain" refers to the smaller of the two types of polypeptide chains found in naturally occurring conformations in antibody molecules. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.

[0028] The term "complementarity determining region" or "CDR" refers to the amino acid sequence in the antibody variable region that imparts antigen specificity and binding affinity. For example, in general, there are three CDRs (e.g., CDR1-H, CDR2-H, and CDR3-H) in each heavy chain variable region, and three CDRs (CDR1-L, CDR2-L, and CDR3-L) in each light chain variable region. The precise amino acid sequence boundaries of CDRs can be determined using any of many well-known schemes, including: Kabat numbering scheme, Chothia numbering scheme, IMGT numbering scheme, AHo numbering scheme, AbM numbering scheme. The precise amino acid sequence of a given CDR or FR may be different due to the different numbering schemes selected. It should be understood that "CDR" or "FR" of a given antibody or its region (e.g., its variable region) encompasses CDRs or FRs defined by any of the above-mentioned schemes or other known schemes. In the case where a specified CDR or FR contains a given amino acid sequence, it should be understood that such CDR or FR can also have the sequence of the corresponding CDR or FR defined by any of the above-mentioned schemes or other known schemes. The numbering scheme used herein to define the boundaries of CDRs and FRs is the Chothia scheme.

[0029] The term "single-chain antibody" or "scFv" refers to a fusion protein comprising at least one light chain variable region (VL) and at least one heavy chain variable region (VH), wherein the light chain variable region and the heavy chain variable region are adjacent (e.g., connected via a linker) and can be expressed in the form of a single-chain polypeptide, and wherein the scFv retains the specificity of the complete antibody from which it is derived. Unless otherwise indicated, the scFv herein may have the VL and VH in any order (e.g., relative to the N-terminus and C-terminus of the polypeptide), and the scFv may comprise VL-linker-VH or VH-linker-VL from the N-terminus to the C-terminus. The term "linker" refers to a molecular sequence that connects two molecules or two sequences on the same molecule. In some embodiments, the linker is a peptide linker. Preferably, the linker does not adversely affect the expression, secretion, or biological activity of the polypeptide. In addition, the linker is preferably not antigenic and does not elicit an immune response. In some embodiments, the linker may be an endogenous amino acid sequence, an exogenous amino acid sequence (e.g., a GS-rich sequence), or a non-peptide chemical linker. In some embodiments, the linker of the present invention has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO:41 or 42.

[0030] The term "single domain antibody" or "sdAb" refers to a single antigen-binding polypeptide having three complementary determining regions (CDRs), including full-length antibodies (e.g., HCAbs) and antigen-binding fragments thereof (e.g., VH, VL, VHH). In some cases, the single domain antibody is selected from or engineered from HCAbs of camel or shark origin, and its heavy chain variable domain is referred to herein as "VHH". VHH has the following basic structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, where FR1 to FR4 refer to framework regions 1 to 4, respectively, and CDR1 to CDR3 refer to complementarity determining regions 1 to 3.

[0031] The term "identity" refers to the extent to which two (nucleotide or amino acid) sequences have the same residue at the same position in an alignment, and is usually expressed as a percentage. Preferably, identity is determined over the entire length of the sequences being compared. Thus, two copies of exactly the same sequence have 100% identity. It is known to those skilled in the art that sequence identity can be determined using algorithms such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25: 3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215: 403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147: 195-197), and ClustalW.

[0032] The term "transmembrane domain" refers to a polypeptide structure that enables cell surface molecules to be expressed on the cell surface and anchors the antigen binding domain to the cell membrane. The transmembrane domain can be natural or synthetic, and can also be derived from any membrane-bound protein or transmembrane protein. When the antigen binding domain binds to the target, the transmembrane domain can carry out signal transduction. Particularly suitable transmembrane domains for use in the present invention can be derived from, for example, TCR α chain, TCR β chain, TCR γ chain, TCR δ chain, CD3 ζ subunit, CD3 ε subunit, CD3 γ subunit, CD3 δ subunit, CD45, CD4, CD5, CD8 α, CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In some embodiments, the transmembrane domain is derived from the following molecules: CD8α, CD4, CD28 or 4-1BB, or the transmembrane domain can be synthetic and can mainly contain hydrophobic residues such as leucine and valine. Preferably, the transmembrane domain is derived from CD28, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 26, or the transmembrane domain is derived from CD8α, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 27 or 28.

[0033] In some embodiments, the chimeric antigen receptor further comprises a hinge region between the antigen binding domain and the transmembrane domain. The term "hinge region" generally refers to any oligopeptide or polypeptide that acts to connect the transmembrane domain to the antigen binding domain. Specifically, the hinge region is used to provide greater flexibility and accessibility for the antigen binding domain. The hinge region can comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids. The hinge region can be derived in whole or in part from natural molecules, such as the extracellular region of CD8, CD4 or CD28, or in whole or in part from an antibody constant region. Alternatively, the hinge region can be a synthetic sequence corresponding to a naturally occurring hinge sequence, or it can be a fully synthetic hinge sequence. Preferably, the hinge region is derived from the hinge region of CD8α, CD28, FcγRIIIα receptor, IgG4 or IgG1, more preferably from the hinge region of CD8α, CD28 or IgG4. In some embodiments, the hinge region is from CD28, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the hinge region is from CD8α, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 30 or 31. In some embodiments, the hinge region is from IgG4, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 32.

[0034] The term "costimulatory domain" refers to at least a portion of a protein that mediates intracellular signal transduction to induce an immune response such as an effector function, and is an intracellular functional signaling domain from a costimulatory molecule, comprising the entire intracellular region of the costimulatory molecule, or a functional fragment thereof. A "costimulatory molecule" refers to a cognate binding partner that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response (e.g., proliferation and survival). The costimulatory signaling domain of any costimulatory molecule is suitable for use in immunosuppressive molecules as described herein. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA, and Toll ligand receptors. The costimulatory domains of the present invention include but are not limited to the intracellular region derived from the following proteins:CD94, LTB, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18, CD27, CD28, CD30, CD40, CD54, CD83, CD134 (OX40), CD137 (4-1BB), CD270 (HVEM), CD272 (BTLA), CD276 (B7-H3), CD278 (ICOS), CD357 (GITR), DAP10, DAP12, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM, ZAP70 and combinations thereof. Preferably, the costimulatory domains of CAR of the present invention are 4-1BB and / or CD28. In some embodiments, the costimulatory domain is from CD28, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 33. In some embodiments, the costimulatory domain is from 4-1BB, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 34 or 35.

[0035] The chimeric antigen receptor of the present invention also comprises a primary signaling domain. The term "primary signaling domain" refers to a protein structure that works together to initiate primary signaling after antigen-receptor binding, which is generally an intracellular sequence of a T cell receptor and a co-receptor. The primary signaling domain generally comprises one or more immunoreceptor tyrosine-based activation motifs (ITAMs). The primary signaling domain of the present invention includes, but is not limited to, intracellular regions derived from the following proteins: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d. In some embodiments, the chimeric antigen receptor of the present invention comprises a CD3ζ primary signaling domain, for example, a CD3ζ primary signaling domain having at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 36 or 37.

[0036] In some embodiments, the chimeric antigen receptor of the present invention further comprises a signal peptide so that when it is expressed in a cell, such as a T cell, the nascent protein is directed to the endoplasmic reticulum and subsequently to the cell surface. The core of the signal peptide may contain a long hydrophobic amino acid segment that has a tendency to form a single α-helix. At the end of the signal peptide, there is usually an amino acid segment that is recognized and cleaved by a signal peptidase. The signal peptidase can cleave during or after translocation to produce a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease. Signal peptides that can be used in the present invention are well known to those skilled in the art, such as signal peptides derived from B2M, CD8α, IgG1, GM-CSFRα, etc. In some embodiments, the signal peptide that can be used in the present invention is derived from B2M and has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, or 99%, or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the signal peptide useful in the present invention is derived from CD8α, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 39 or 40.

[0037] b. Exogenous genes

[0038] The term "XCL1," also known as lymphoid chemokine 1, is a member of the C-type chemokine family, primarily produced by CD8+ T cells and natural killer cells. XCL1 has unique sequence characteristics and two interconvertible protein spatial conformations, which distinguish it from other chemokines and allow it to exert unique functions. The XCL1-specific receptor, XCR1, is a member of the G protein-coupled receptor family. The interaction between the two not only plays an important role in negative selection and the establishment of autoimmune tolerance in the thymus, but also initiates cross-antigen presentation and mediates cytotoxic immune responses. XCL1 not only regulates the balance of the immune system and maintains intestinal immune homeostasis, but is also associated with a variety of diseases, such as autoimmune diseases, nephritis, tuberculosis, and human immunodeficiency virus infection.

[0039] In some embodiments, the XCL1 used in the present invention can be wild-type XCL1, a variant thereof, or a functional fragment thereof, wherein the variant or functional fragment has the same or similar biological function as wild-type XCL1. Specifically, the XCL1 used in the present invention has at least 70%, preferably at least 80%, and more preferably at least 90%, 95%, 97%, 99%, or 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1 or 2.

[0040] The term "Fc" refers to the C-terminal region of the immunoglobulin heavy chain, which contains at least part of the constant region. Fc has no antigen binding activity and is the site where the immunoglobulin interacts with effector molecules or cells. The term includes native Fc and variant Fc. "Native Fc" refers to a molecule or sequence comprising a non-antigen binding fragment produced by digesting a whole antibody, whether in monomeric or multimeric form. The immunoglobulin source that produces native Fc is preferably derived from humans. Native Fc is composed of monomeric polypeptides that can be linked into dimer or multimeric forms by covalent linkages (e.g., disulfide bonds) and non-covalent linkages. Depending on the class (e.g., IgG, IgA, IgE, IgD, IgM) or subtype (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2), there are 1-4 intermolecular disulfide bonds between the monomer subunits of the native Fc molecule. An example of a native Fc is a disulfide-linked dimer produced by digesting IgG with papain (see Ellison et al. (1982), Nucleic Acids Res. 10:4071-9). The term "native Fc" as used herein generally refers to monomeric, dimeric, and multimeric forms. The term "variant Fc," also referred to as "Fc variant," refers to a variant or fragment that contains at least one amino acid modification (i.e., substitution, deletion, or insertion) compared to the amino acid sequence of a native Fc but retains the biological activity (e.g., receptor binding activity) of the native Fc.

[0041] In some embodiments, the Fc of the present invention is derived from a native Fc or variant Fc of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD, or a hybrid Fc of any two of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD, preferably a native Fc or variant Fc of IgG1, IgG2, IgG3, or IgG4, or a hybrid Fc of IgG4 and IgD. In a specific embodiment, the Fc of the present invention has a sequence identity of at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99%, or 100% to SEQ ID NO: 3.

[0042] The expression of the exogenous genes XCL1 and / or Fc in the present invention can be constitutive or conditional. In some embodiments, the expression of the exogenous genes XCL1 and / or Fc is conditional. For example, as needed, the exogenous genes of the present invention can be operably linked to inducible, repressible, or tissue-specific promoters to regulate the expression level of the introduced exogenous genes at a specific time or in a specific tissue or cell type. In some embodiments, the promoter is an inducible promoter, i.e., a promoter that initiates transcription only under specific environmental conditions, developmental conditions, or in the presence of an inducer. In other embodiments, the promoter is a repressible promoter, i.e., in the presence of a repressor specific for the repressible promoter, the expression of the exogenous gene in the cell is inhibited or not expressed.

[0043] In some embodiments, the exogenous gene XCL1 and / or Fc can be operably linked to a localization domain, which can localize the exogenous gene of the present invention for expression at a specific cellular location, such as the cell membrane. Localization domains include, but are not limited to, nuclear localization signals, leader peptides, transmembrane domains, etc. In one embodiment, the exogenous gene XCL1 and / or Fc of the present invention is operably linked to a transmembrane domain, thereby anchoring the expression on the surface of the engineered cell.

[0044] c. Cells

[0045] The present invention also provides an engineered cell expressing cell surface molecules that specifically recognize antigens and exogenous XCL1 and Fc.

[0046] In some embodiments, the engineered cells of the invention are engineered immune cells.

[0047] The term "immune cell" refers to any cell with one or more effector functions (for example, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and / or CDC) of the immune system. For example, immune cell can be a B cell, T cell, macrophage, neutrophil, dendritic cell, monocyte, NK cell or NKT cell. Immune cell can be obtained from a variety of sources, for example, from a subject (for example, from the subject's peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from infection site, ascites, pleural effusion, spleen tissue, tumor etc. separation and obtain), or from a cell line (such as Jurkat, SupT1, NK92 etc.) cultured in vitro, or from stem cell differentiation (for example, derived from cord blood stem cell, progenitor cell, bone marrow stem cell, hematopoietic stem cell, adult stem cell, embryonic stem cell, pluripotent stem cell, iPSC etc.). Preferably, immune cell is a T cell or NK cell, more preferably a T cell. T cell can also be concentrated or purified. T cells can be at any developmental stage, including but not limited to CD4+CD8+T cells, CD4+T cells (e.g., Th1 and Th2 cells), CD8+T cells (e.g., cytotoxic T cells), CD4-CD8-T cells, tumor-infiltrating cells, memory T cells, naive T cells, γδ-T cells, αβ-T cells, etc. Preferably, the immune cells are human T cells, which can be obtained using a variety of techniques known to those skilled in the art, such as isolating T cells from the subject's blood using Ficoll.

[0048] In other embodiments, the engineered cells of the invention are engineered stem cells.

[0049] The term "stem cell" is a primitive cell with the potential for self-replication, multidirectional differentiation and homing. It is the origin cell of the body and the ancestral cell that forms various tissues and organs of the human body. In the process of cell differentiation, due to the uneven distribution of regulatory differentiation proteins in the cytoplasm, a daughter cell irreversibly moves towards the terminal of differentiation and becomes a differentiated cell with a specific function, until it completely loses the ability to divide again and eventually ages and dies. In order to make up for this deficiency, the body retains a part of the undifferentiated primitive cells, which retain the characteristics of the parent. This part of the undifferentiated primitive cells that are retained are called stem cells. Once needed, these stem cells can produce differentiated cells by dividing according to the developmental pathway. The stem cells described in the present invention can be embryonic stem cells, adult stem cells (such as umbilical cord blood stem cells, bone marrow stem cells, hematopoietic stem cells, mesenchymal stem cells, etc.) and pluripotent stem cells (such as induced pluripotent stem cells iPSC, etc.).

[0050] In some embodiments, the immune cells of the present invention further comprise expression of at least one endogenous gene that is suppressed or silenced, and the endogenous gene is selected from the following: CD52, GR, TCRα, TCRβ, CD3γ, CD3δ, CD3ε, CD3ζ, HLA-I, HLA-II, B2M, immune checkpoint genes such as PD1, CTLA-4, LAG3 and TIM3. More particularly, the expression of at least TCR components (including TCRα, TCRβ genes) or CD3 components (including CD3γ, CD3δ, CD3ε, CD3ζ) in immune cells is suppressed or silenced. This strategy is particularly useful for avoiding graft-versus-host disease (GvHD). Methods for suppressing or silencing genes are known in the art, for example, by mediating DNA breakage by Cas enzymes in large-range nucleases, zinc finger nucleases, TALEN nucleases or CRISPR systems, thereby knocking out the gene; or suppressing gene expression by means of shRNA, RNAi, etc.

[0051] II. Nucleic Acids and Vectors

[0052] The present invention also provides a nucleic acid molecule comprising a nucleic acid sequence encoding a cell surface molecule that specifically recognizes an antigen, a nucleic acid sequence encoding Fc, and a nucleic acid sequence encoding XCL1.

[0053] The term "nucleic acid molecule" includes sequences of ribonucleotides and deoxyribonucleotides, such as modified or unmodified RNA or DNA, each in single-stranded and / or double-stranded form, linear or circular, or mixtures thereof (including hybrid molecules). Thus, nucleic acids according to the present invention include DNA (such as dsDNA, ssDNA, cDNA), RNA (such as dsRNA, ssRNA, mRNA, ivtRNA), combinations thereof, or derivatives thereof (such as PNA). Preferably, the nucleic acid is DNA or RNA, more preferably mRNA.

[0054] The present invention also provides a vector comprising the nucleic acid described herein. The nucleic acid sequence encoding the cell surface molecule that specifically recognizes the antigen, the nucleic acid sequence encoding Fc, and the nucleic acid sequence encoding XCL1 can be located in one or more vectors. When located in a single vector, the nucleic acid sequences can be operably linked via a 2A peptide.

[0055] The term "vector" is a nucleic acid molecule used as a medium for transferring (foreign) genetic material into a host cell where it can, for example, be replicated and / or expressed.

[0056] Vector generally includes targeting vector and expression vector. "Targeting vector" is a medium for delivering isolated nucleic acid to the interior of the cell by, for example, homologous recombination or using a hybrid recombinase of a sequence at a specific targeting site. "Expression vector" is a vector for the transcription of heterologous nucleic acid sequences (such as those encoding chimeric antigen receptor polypeptides of the present invention) in suitable host cells and the translation of their mRNA. Suitable vectors that can be used for the present invention are known in the art, and many are commercially available. In one embodiment, the vector of the present invention includes but is not limited to plasmids, viruses (such as retroviruses, oncolytic viruses, slow viruses, adenoviruses, vaccinia viruses, Rous sarcoma viruses, polyoma viruses and adeno-associated viruses, etc.), phages, phagemids, cosmids and artificial chromosomes (including BAC and YAC). The vector itself is typically a nucleotide sequence, typically a DNA sequence comprising an insert (transgene) and a larger sequence as a vector "skeleton". Engineered vectors are also typically included in the starting point of autonomous replication in the host cell (if stable expression of polynucleotides is required), a selection marker and a restriction enzyme cleavage site (such as a multiple cloning site, MCS). The vector may further comprise elements such as a promoter, a polyadenylic acid tail (polyA), a 3'UTR, an enhancer, a terminator, an insulator, an operator, a selection marker, a reporter gene, a targeting sequence and / or a protein purification tag. In a specific embodiment, the vector is an in vitro transcription vector.

[0057] III. Pharmaceutical Compositions and Combination Therapies

[0058] The present invention also provides a pharmaceutical composition comprising the engineered cells, nucleic acid molecules, or vectors described herein as active agents and one or more pharmaceutically acceptable excipients. Therefore, the present invention also encompasses the use of the nucleic acid molecules, vectors, or engineered cells in the preparation of pharmaceutical compositions.

[0059] The term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient (i.e., capable of inducing the desired therapeutic effect without causing any undesirable local or systemic effects), and is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). Examples of pharmaceutically acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coatings, adsorbents, antiadherents, glidants, antioxidants, flavorings, colorants, sweeteners, solvents, cosolvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coatings, isotonic agents, absorption delaying agents, stabilizers, and tension modifiers. It is known to those skilled in the art to select suitable excipients to prepare the pharmaceutical compositions desired in the present invention. Exemplary excipients for use in the pharmaceutical compositions of the present invention include saline, buffered saline, glucose, and water. In general, the choice of suitable excipients depends on, inter alia, the active agent used, the disease to be treated and the desired dosage form of the pharmaceutical composition.

[0060] The pharmaceutical composition according to the present invention can be applied in a variety of ways. Typically, administration is accomplished parenterally. Parenteral delivery methods include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual, or intranasal administration.

[0061] The pharmaceutical compositions according to the present invention may also be administered in combination with one or more other pharmaceutical agents suitable for the treatment and / or prevention of the disease to be treated.

[0062] IV. Therapeutic Applications

[0063] The present invention also provides a method for treating a subject suffering from cancer, infection, or autoimmune disease, comprising administering to the subject an effective amount of a nucleic acid molecule, vector, engineered cell, or pharmaceutical composition according to the present invention. Therefore, the present invention also encompasses the use of the nucleic acid molecule, vector, or engineered cell in the preparation of a medicament for treating cancer, infection, or autoimmune disease.

[0064] In some embodiments, the treatment method comprises administering to the subject an effective amount of the engineered cells and / or pharmaceutical compositions of the invention.

[0065] The term "subject" refers to a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing animal models of cancer. Preferably, the subject is a human.

[0066] In some embodiments, the cancer is a cancer associated with expression of a target to which a functional exogenous receptor binds. For example, the cancer includes, but is not limited to, brain gliomas, blastomas, sarcomas, leukemias, basal cell carcinomas, biliary tract cancer, bladder cancer, bone cancer, brain and CNS cancers, breast cancer, peritoneal cancer, cervical cancer, choriocarcinoma, colon and rectal cancer, connective tissue cancer, cancers of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer (including gastrointestinal cancer), glioblastoma (GBM), liver cancer, hepatoma, intraepithelial neoplasia, kidney cancer, laryngeal cancer, liver tumors, lung cancers (e.g., small cell lung cancer, non-small cell lung cancer, adenocarcinoma and squamous lung cancer), lymphoma (including Hodgkin lymphoma and non-Hodgkin lymphoma), melanoma, myeloma, neuroblastoma, oral cancer (e.g., lip, tongue, mouth, and pharynx), ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, cancers of the respiratory system, salivary gland cancer, skin cancer, squamous cell carcinoma, stomach cancer, testicular cancer, thyroid cancer, uterine or endometrial cancer, malignancies of the urinary system, vulvar cancer, and other carcinomas and sarcomas, and B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL) ), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-cleaved cell NHL, large mass disease NHL), mantle cell lymphoma, AIDS-related lymphoma, and Waldenstrom macroglobulinemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic myeloid leukemia (CML), malignant lymphoproliferative disease, MALT lymphoma, hairy cell leukemia, marginal zone lymphoma, multiple myeloma, myelodysplasia, plasmablastic lymphoma, preleukemia, plasmacytoid dendritic cell neoplasm, and post-transplantation lymphoproliferative disorder (PTLD); and other diseases related to target expression. Preferably, the disease that can be treated with the engineered cells or pharmaceutical compositions of the present invention is selected from: leukemia, lymphoma, multiple myeloma, brain glioma, pancreatic cancer, gastric cancer, etc.

[0067] In some embodiments, the infection includes, but is not limited to, infections caused by viruses, bacteria, fungi, and parasites.

[0068] In some embodiments, the autoimmune diseases include but are not limited to type I diabetes, celiac disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, Addison's disease, Sjögren's syndrome, Hashimoto's thyroiditis, myasthenia gravis, vasculitis, pernicious anemia, and systemic lupus erythematosus.

[0069] In some embodiments, the method further comprises administering to the subject one or more additional chemotherapeutic agents, biologics, drugs or treatments. In this embodiment, the chemotherapeutic agent, biologic, drug or treatment is selected from radiation therapy, surgery, antibody reagents and / or small molecules and any combination thereof.

[0070] The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with examples. It should be noted that those skilled in the art should understand that the accompanying drawings and embodiments of the present invention are for illustrative purposes only and do not constitute any limitation to the present invention. The embodiments of the present invention and the features thereof may be combined with each other unless there is any contradiction. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1: CAR expression levels of various CAR-T cells targeting CD19 as determined by flow cytometry.

[0072] Figure 2: Mouse XCL1 levels in the supernatant of various CD19-targeting CAR-T cells cultured until D5.

[0073] Figure 3: Target cell killing levels after co-incubation of various CD19-targeting CAR-T cells with target cells at effector-target ratios of 5:1, 1:1, 1:5, and 1:10.

[0074] Figure 4: IFN-γ release levels of various CD19-targeting CAR-T cells after co-culture with target cells.

[0075] Figure 5: Tumor growth in mice in each CAR-T cell treatment group in the Panc02-mCD19 subcutaneous tumor model of B6 mice.

[0076] Figure 6: Body weight of mice in each CAR-T cell treatment group in the Panc02-mCD19 subcutaneous tumor model of B6 mice.

[0077] FIG7 : CAR expression levels of each CAR-T cell targeting Claudin 18.2 were determined by flow cytometry.

[0078] FIG8 : Mouse XCL1 levels in the supernatant of each CAR-T cell targeting Claudin 18.2 cultured until D5.

[0079] Figure 9: Target cell killing levels after co-incubation of various CAR-T cells targeting Claudin 18.2 with target cells at effector-target ratios of 5:1, 1:1, 1:5, and 1:10.

[0080] Figure 10: IFN-γ release levels of various CAR-T cells targeting Claudin 18.2 after co-culture with target cells.

[0081] Figure 11: Tumor growth in mice in each CAR-T cell treatment group in the Panc02-18.2 subcutaneous tumor model of B6 mice.

[0082] Figure 12: Body weight of mice in each CAR-T cell treatment group in the Panc02-18.2 subcutaneous tumor model of B6 mice. DETAILED DESCRIPTION

[0083] Example 1. Construction of CAR-T cells targeting mouse CD19 expressing XCL1 Fc fusion protein

[0084] 1.1 Construction of cCART cells targeting mouse CD19

[0085] An MSCV-mCD19 scFv plasmid was constructed, which contained the following structures linked in sequence: anti-mouse CD19 scFv (SEQ ID NO: 12), CD8α hinge region (SEQ ID NO: 31), CD8α transmembrane region (SEQ ID NO: 28), and CD3ζ intracellular region (SEQ ID NO: 37).

[0086] To a sterile tube, add 3 ml of Opti-MEM (Gibco), 45 μg of the prepared retroviral plasmid, and 15 μg of the packaging vector pCL-Eco (Shanghai Hewu Biotechnology Co., Ltd.). Then, add 120 μl of X-treme GENE HP DNA transfection reagent (Roche), mix immediately, and incubate at room temperature for 15 minutes. The plasmid / vector / transfection reagent mixture is then added dropwise to a 293T cell culture flask and incubated at 37°C, 5% CO2. 72 hours after transfection, the culture is harvested and centrifuged to obtain the retroviral supernatant.

[0087] T cells were activated with anti-CD3 and anti-CD28 antibodies (Thermofisher) and cultured for 2 days at 37°C and 5% CO2. Then, retroviral supernatant containing MSCV-mCD19 scFv was added, and after 3 days of culture, CAR-T cells containing anti-CD19 scFv (CAR19-T) were obtained.

[0088] 1.2 Construction of XCL1 CART cells targeting mouse CD19 expressing secreted XCL1

[0089] An MSCV-XCL1 plasmid was constructed, which contained the following construct: mouse XCL1 (SEQ ID NO: 1).

[0090] Retrovirus was prepared according to the method of Example 1.1, and activated T cells were infected with a combination of retrovirus containing MSCV-mCD19 scFv prepared in Example 1.1 and retrovirus containing MSCV-XCL1 to obtain CAR19+XCL1-T cells (expressing anti-CD19 CAR and mouse secretory XCL1).

[0091] 1.3 Construction of CAR19+XCL1 Fc cells targeting mouse CD19 expressing XCL1 Fc fusion protein

[0092] An MSCV-XCL1 Fc plasmid was constructed, which contained the following structures linked in sequence: mouse XCL1 (SEQ ID NO: 1), IgD+IgG4 Fc (SEQ ID NO: 3).

[0093] Retrovirus was prepared according to the method of Example 1.1, and activated T cells were infected with a combination of retrovirus containing MSCV-mCD19 scFv prepared in Example 1.1 and retrovirus containing MSCV-XCL1 Fc to obtain CAR19+XCL1 Fc-T cells (expressing anti-CD19 CAR and XCL1 Fc fusion protein).

[0094] Using flow cytometry, anti-human F(ab) antibody + PE-Streptavidin antibody were used to detect the expression of anti-mouse CD19 scFv antibody in CAR-T cells. It can be seen that the CAR in the CAR-T cells prepared by the present invention can be effectively expressed (Figure 1).

[0095] Example 2. Detection of XCL1 levels in each CAR-T cell targeting CD19 by ELISA

[0096] On the fifth day (D5) of CART cell culture, the supernatants of NT cells, CAR19-T cells, CAR19+XCL1-T cells, and CAR19+XCL1 Fc-T cell cultures were collected, and the XCL1 content was detected using the mouse XCL1 DuoSet ELISA Kit (R&D systems). The results are shown in Figure 2.

[0097] It can be seen that the XCL1 level of CAR19+XCL1 Fc-T cells was significantly higher than that of other groups. This indicates that CAR19+XCL1 Fc-T cells expressing XCL1 Fc fusion protein can promote the secretion of XCL1.

[0098] Example 3. Detection of the killing level of target cells by each CAR-T cell targeting CD19

[0099] 1×10 4 The target cells Panc02-mCD19-luci cells were plated into 96-well plates at a concentration of 10 cells / well, and then NT cells, CAR19-T cells, CAR19+XCL1-T cells, and CAR19+XCL1 Fc-T cells were plated into 96-well plates at different effector-target ratios of 5:1, 1:1, 1:5, and 1:10 for co-culture. After 18 hours, the fluorescence value was measured using a microplate reader. The killing efficiency was calculated according to the formula: (target cell fluorescence mean - sample fluorescence mean) / target cell fluorescence mean × 100%, and the results are shown in Figure 3.

[0100] It can be seen that at different effector-target ratios, CAR19+XCL1 Fc-T cells expressing XCL1 Fc fusion protein showed higher target cell killing activity than CAR19+XCL1 T cells and CAR19-T cells expressing conventional XCL1. This indicates that CAR19+XCL1 Fc-T cells expressing XCL1 Fc fusion protein can enhance the killing activity of CART cells against target cells.

[0101] Example 4. Detection of IFN-γ production ability of each CAR-T cell targeting CD19

[0102] 1×10 4 Target cells Panc02-mCD19-luci cells and non-target cells Pan02-luci were plated into 96-well plates at a concentration of 10 cells / well. NT cells, CAR19-T cells, CAR19+XCL1-T cells, and CAR19+XCL1 Fc-T cells were then plated into 96-well plates at an effector-target ratio of 20:1 for co-culture. After culturing at 37°C for 18 hours, the cell supernatant was collected and the IFN-γ content was detected using the mouse IFN-gamma DuoSet ELISA Kit (R&D systems). The results are shown in Figure 4.

[0103] It can be seen that when co-incubated with target cells Panc02-mCD19-luci cells, the IFN-γ release levels of CAR19+XCL1-T cells and CAR19+XCL1Fc-T cells were comparable to those of CAR19-T cells. This indicates that the expression of XCL1 and Fc did not affect the IFN-γ production ability of CAR-T cells.

[0104] Example 5. Detection of the therapeutic ability of each CAR-T cell targeting CD19 expressing XCL1 Fc fusion protein in a Panc02-mCD19 cell tumor-bearing model injected subcutaneously in B6 mice

[0105] Twenty-four 5-week-old B6 mice were selected and injected subcutaneously into the right upper back with 100 μL of a PBS suspension of Panc02-mCD19 tumor cells at a concentration of 10e6 / mL. Tumor growth was observed and recorded every day. On day 8, NT cells, CAR19-T cells, CAR19+XCL1-T cells, and CAR19+XCL1 Fc-T cells were prepared according to Example 1. On day 10, the average tumor volume was 100 mm 3 At the time of the study, the mice were randomly divided into 4 groups according to the size of the tumor, with 6 mice in each group, namely NT group, CAR19 group, CAR19+XCL1 group and CAR19+XCL1 Fc group. Each mouse was intraperitoneally injected with 5 mg of CPA to eliminate its own immune cells. On the 13th day, the CART cells in each group were prepared into a PBS suspension with a concentration of 5e6 / mL, and 200 μl of CART cell suspension was injected into the tail vein of the corresponding group of mice. The status of the mice was observed every day, and the body weight and tumor growth were recorded.

[0106] The tumor growth is shown in Figure 5. It can be seen that the tumor growth rate of the CAR19+XCL1 Fc group was significantly reduced compared with the CAR19+XCL1 group and the CAR19 group. This indicates that in the Panc02-mCD19 tumor-bearing model of B6 mice, CAR19+XCL1 Fc-T cells expressing XCL1 Fc fusion protein can significantly enhance the killing activity of CART cells against target tumors.

[0107] The changes in mouse weight are shown in Figure 6. There was no difference in the weight of mice in each group, which indicates that in the Panc02-mCD19 tumor-bearing model of B6 mice, CAR19+XCL1 Fc-T cells expressing XCL1 Fc fusion protein did not enhance the toxicity of CART cells to the host.

[0108] Example 6. Construction of Claudin 18.2-targeted CAR-T cells expressing XCL1 Fc fusion protein

[0109] 6.1 Construction of cCART cells targeting mouse Claudin 18.2

[0110] An MSCV-Claudin 18.2 VHH plasmid was constructed, comprising the following structures linked in sequence: anti-mouse Claudin 18.2 VHH (SEQ ID NO: 25), CD8α hinge region (SEQ ID NO: 31), CD8α transmembrane region (SEQ ID NO: 28), 4-1BB costimulatory domain (SEQ ID NO: 35), and CD3ζ intracellular region (SEQ ID NO: 37). Retrovirus containing MSCV-Claudin 18.2 VHH was prepared according to the method of Example 1.1.

[0111] T cells were activated with anti-CD3 and anti-CD28 antibodies (Thermofisher) and cultured for 2 days at 37°C and 5% CO2. Then, retroviral supernatant containing MSCV-Claudin 18.2 VHH was added, and after 3 days of culture, CAR-T cells containing Claudin 18.2 VHH (CAR18.2) were obtained.

[0112] 6.2 Construction of XCL1 CART cells expressing secreted XCL1 targeting mouse Claudin 18.2

[0113] An MSCV-XCL1 plasmid was constructed, which contained the following construct: mouse XCL1 (SEQ ID NO: 1).

[0114] Retrovirus was prepared according to the method of Example 1.1, and activated T cells were infected with a combination of retrovirus containing MSCV-Claudin 18.2 VHH and retrovirus containing MSCV-XCL1 to obtain CAR18.2+XCL1-T cells (expressing anti-Claudin 18.2 CAR and mouse secretory XCL1).

[0115] 6.3 Construction of CAR18.2+XCL1 Fc Cells Expressing XCL1 Fc Fusion Protein Targeting Mouse Claudin 18.2

[0116] An MSCV-XCL1 Fc plasmid was constructed, which contained the following structures linked in sequence: mouse XCL1 (SEQ ID NO: 1), IgD+IgG4 Fc (SEQ ID NO: 3).

[0117] Retrovirus was prepared according to the method of Example 1.1, and activated T cells were infected with a combination of retrovirus containing MSCV-Claudin 18.2 VHH and retrovirus containing MSCV-XCL1 Fc to obtain CAR18.2+XCL1 Fc-T cells (expressing anti-Claudin 18.2 CAR and XCL1 Fc fusion protein).

[0118] Using flow cytometry, anti-human F(ab) antibody + PE-Streptavidin antibody were used to detect the expression of anti-mouse VHH antibodies in CAR-T cells. It can be seen that the CAR in the CAR-T cells prepared by the present invention can be effectively expressed ( Figure 7 ).

[0119] Example 7. Detection of XCL1 levels in each CAR-T cell targeting Claudin 18.2 by ELISA

[0120] On the 5th day (D5) of CART cell culture, the supernatant of NT cells, CAR18.2-T cells, CAR18.2+XCL1-T cells, and CAR18.2+XCL1 Fc-T cell culture fluid was collected, and the XCL1 content was detected using the mouse XCL1 DuoSet ELISA Kit (R&D systems). The results are shown in Figure 8.

[0121] It can be seen that the XCL1 expression level of CAR18.2+XCL1 Fc-T cells was significantly higher than that of other groups. This indicates that CAR18.2+XCL1 Fc-T cells expressing XCL1 Fc fusion protein can promote the secretion of XCL1.

[0122] Example 8. Detection of the killing level of target cells by each CAR-T cell targeting Claudin 18.2

[0123] 1×10 4 The target cells Panc02-Claudin 18.2-luci cells were plated into 96-well plates at a concentration of 10 cells / well, and then NT cells, CAR18.2-T cells, CAR18.2+XCL1-T cells, and CAR18.2+XCL1Fc-T cells were plated into 96-well plates at different effector-target ratios of 5:1, 1:1, 1:5, and 1:10 for co-culture. After 18 hours, the fluorescence value was measured using a microplate reader. The killing efficiency was calculated according to the calculation formula: (target cell fluorescence mean - sample fluorescence mean) / target cell fluorescence mean × 100%, and the results are shown in Figure 9.

[0124] It can be seen that at different effector-target ratios, CAR18.2+XCL1 Fc-T cells expressing XCL1 Fc fusion protein have higher cytotoxicity against target cells than CAR18.2+XCL1 T cells and CAR18.2-T cells expressing conventional XCL1. This indicates that CAR18.2+XCL1 Fc-T cells expressing XCL1 Fc fusion protein can enhance the cytotoxicity of CART cells against target cells.

[0125] Example 9. Detection of IFN-γ Production Ability of Each CAR-T Cell Targeting Claudin 18.2

[0126] 1×10 4 Target cells Panc02-Claudin 18.2-luci cells and non-target cells Pan02-luci were plated into 96-well plates at a concentration of 10 cells / well. Then, NT cells, CAR18.2-T cells, CAR18.2+XCL1-T cells, and CAR18.2+XCL1 Fc-T cells were plated into 96-well plates at an effector-target ratio of 20:1 for co-culture. After culturing at 37°C for 18 hours, the cell supernatant was collected and the IFN-γ content was detected using the mouse IFN-gamma DuoSet ELISA Kit (R&D systems). The results are shown in Figure 10.

[0127] It can be seen that when co-incubated with target cells Panc02-Claudin 18.2-luci cells, the IFN-γ release levels of CAR18.2+XCL1-T cells and CAR18.2+XCL1 Fc-T cells were comparable to those of CAR18.2-T cells. This indicates that the expression of XCL1 and Fc did not affect the IFN-γ production ability of CAR-T cells.

[0128] Example 10. Detection of the therapeutic ability of CAR-T cells targeting Claudin 18.2 expressing XCL1 Fc fusion protein in a B6 mouse subcutaneous injection Panc02-Claudin 18.2 cell tumor-bearing model

[0129] Twenty-four 5-week-old B6 mice were selected and injected subcutaneously into the right upper back with 100 μL of a PBS suspension of Panc02-Claudin 18.2 tumor cells at a concentration of 10e6 / mL. Tumor growth was observed and recorded daily. On day 8, NT cells, CAR18.2-T cells, CAR18.2+XCL1-T cells, and CAR18.2+XCL1 Fc-T cells were prepared according to Example 1. On day 10, the average tumor volume was 100 mm 3At the time of the study, mice were randomly divided into four groups according to tumor size, with 6 mice in each group, namely NT cells, CAR18.2 group, CAR18.2+XCL1 group, and CAR18.2+XCL1 Fc group. Each mouse was intraperitoneally injected with 5 mg of CPA to eliminate its own immune cells. On the 13th day, each group of CART cells was prepared into a PBS suspension with a concentration of 5e6 / mL, and 200 ul of CART cell suspension was injected into the tail vein of mice in the corresponding group. The status of the mice was observed every day, and the body weight and tumor growth were recorded.

[0130] The tumor growth is shown in Figure 11. It can be seen that the tumor growth rate of the CAR18.2+XCL1 Fc group was significantly reduced compared with the CAR18.2 group and the CAR18.2+XCL1 group. This indicates that in the Panc02-Claudin 18.2 tumor-bearing model of B6 mice, CAR18.2+XCL1 Fc-T cells expressing XCL1 Fc fusion protein can significantly enhance the killing activity of CART cells against target tumors.

[0131] The changes in mouse weight are shown in Figure 12. There was no difference in the weight of mice in each group, which indicates that in the Panc02-Claudin 18.2 tumor-bearing model of B6 mice, CAR18.2+XCL1 Fc-T expressing XCL1 Fc fusion protein did not enhance the toxicity of CART cells to the host.

[0132] The above results indicate that the combination of expressing exogenous genes XCL1 and Fc can effectively enhance the inhibitory effect of CAR-expressing engineered cells on tumor cells.

[0133] It should be noted that the above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may be modified and varied in various ways. It is understood by those skilled in the art that any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.

Claims

1. An engineered cell expressing a cell surface molecule that specifically recognizes an antigen and exogenous XCL1 and Fc. 2 . The engineered cell according to claim 1 , wherein the XCL1 has at least 90% identity to the amino acid sequence shown in SEQ ID NO: 1 or 2. 3 .

3. The engineered cell according to claim 1, wherein the Fc is derived from a natural Fc or variant Fc of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, IgD, or a hybrid Fc of any two of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, IgD, preferably derived from a natural Fc or variant Fc of IgG1, IgG2, IgG3, IgG4, or a hybrid Fc of IgG4 and IgD. The engineered cell according to claim 3 , wherein the Fc has at least 90% identity with the amino acid sequence shown in SEQ ID NO:

3.

5. The engineered cell according to any one of claims 1-4, wherein the cell surface molecule that specifically recognizes an antigen comprises an extracellular domain that specifically recognizes an antigen, and the cell surface molecule is selected from a chimeric antigen receptor, a T cell receptor, a T cell receptor fusion protein, a T cell antigen coupler, and an immune mobilizing monoclonal T cell receptor.

6. The engineered cell according to claim 5, wherein the antigen is selected from the group consisting of: ALK, ADRB3, AKAP-4, APRIL, ASGPR1, BCMA, B7H3, B7H4, B7H6, bcr-abl, BORIS, BST2, BAFF-R, BTLA, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD24, CD25, CD28, CD30, CD33, CD38, CD40, CD44, CD44v6, CD44v7 / 8, CD47, CD52, CD56, CD57, CD58, CD70, CD72, CD79a, CD79b, CD80, CD8 1. CD86, CD97, CD123, CD133, CD137, CD138, CD151, CD171, CD179a, CD300LF, CDH16, CSPG4, CS1, Claudin 6. Claudin 18.1, Claudin 18.2, CEA, CEACAM6, CLL1, c-Met, CAIX, CXORF61, CA125, CYP1B1, CS1, ELF2M, EGFR, EPCAM, EGFRvIII, EphA2, ERG / TMPRSS2ETS fusion gene, ETV6-AML, EMR2, EGP2, EGP40, FAP, FAR, FB P, FLT3, FOSL1, FCRL5, FCAR, Flt3, Flt4, Frizzled, GD2, GD3, gp100, gp130, GM3, GPC2, GPC3, GPRC5D, GPR20, GloboH, GHRHR, GHR, GITR, Her2, HER3, HER-4, HMWMAA, HAVCR1, HPV E6,E7, HVEM, HIV-1Gag, HLA-A1, HLA-A2, IL6R, IL-11Ra, IL-13Ra, IGF-I receptor, LTPR, LIFRP, LRP5, IGLL1, IGF1R, KIT, Kappa Light Chain, KDR, LewisY, LMP2, LY6K, LAGE-1a, legumain, LCK, LAIR1, LILRA2, LY75, MSLN, MUC1, MUC16, MAGE-A1, MAGE3, MAD-CT-1, MelanA / MART1, ML-IAP, MYCN, mut hsp70-2, NCAM, NY-BR-1, NY-ESO-1, NA17, Notch-1-4, nAchR, NKG2D, NKG2D ligand, OY-TES1, OR51E2, OX40, PRSS21, PSCA, PD1, PD-L1, PD-L2, PSMA, Prostase, PAP, PDGFR-β, PCTA-1 / galectin 8, p53, p53 mutant, prostein, PLAC1, PANX3, PAX3, PAX5, PTCH1, RANK, RAGE-1, ROR1, Ras mutant, RhoC, RU1, RU2, Robol, SSEA-4, SSX2, SART3, Sp17, TSHR, Tn Ag, TGS5, TEM1 / CD248, TEM7R, TARP, TCRα, TCRβ, TGFBR1, TGFBR2, TNFRSF4, TWEAK-R, TLR7, TLR9, TAG72, TROP-2, Tie 2, TRP-2, TNFR1, TNFR2, TEM1, UPK2VEGFR, WT1, XAGE1, 5T4, 8H9, αvβ6 integrin, CA9, folate receptor α, ephrin B2, tyrosinase, fucosyl GM1, o-acetyl-GD2, folate receptor β, polysialic acid, sperm protein 17, survivin and telomerase, sarcoma translocation breakpoints, human telomerase / hTERT, androgen receptor, intestinal carboxylesterase, cyclin B1, fibronectin, tenascin, oncofetal variant of tumor necrosis zone, and any combination thereof. , 7. The engineered cell of claim 6, wherein the chimeric antigen receptor comprises an antigen binding domain, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a co-stimulatory domain and / or a primary signaling domain.

8. The engineered cell according to claim 7, wherein the antigen binding domain is selected from the group consisting of a complete antibody, Fab, Fab', F(ab')2, Fd fragment, Fd', Fv fragment, scFv, sdFv, linear antibody, diabody, sdAb and a functional fragment of a ligand or receptor.

9. The engineered cell according to claim 7 or 8, wherein the transmembrane domain is selected from the transmembrane domains of the following proteins: TCRα chain, TCRβ chain, TCRγ chain, TCRδ chain, CD3ζ subunit, CD3ε subunit, CD3γ subunit, CD3δ subunit, CD45, CD4, CD5, CD8α, CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.

10. The engineered cell according to any one of claims 7-9, wherein the primary signaling domain is selected from the intracellular region of the following proteins: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b and CD66d.

11. The engineered cell according to any one of claims 7-10, wherein the co-stimulatory domain comprises one or more intracellular regions selected from the group consisting of CD94, LTB, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18, CD27, CD28, CD30, CD40, CD54, CD83, CD134, CD137, CD270, CD272, CD276, CD278, CD357, DAP10, DAP12, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM, and ZAP70.

12. The engineered cell according to any one of claims 1-11, wherein the cell is an immune cell selected from the group consisting of T cells, NK cells, NKT cells, B cells, monocytes, macrophages, neutrophils, dendritic cells, and any combination thereof.

13. The engineered cell according to claim 12, wherein the cell is selected from CD4+CD8+T cells, CD4+T cells, CD8+T cells, CD4-CD8-T cells, tumor infiltrating cells, memory T cells, naive T cells, γδ-T cells and αβ-T cells.

14. The engineered cell according to any one of claims 1-11, wherein the cell is a stem cell selected from the group consisting of embryonic stem cells, umbilical cord blood stem cells, bone marrow stem cells, hematopoietic stem cells, mesenchymal stem cells and induced pluripotent stem cells.

15. A nucleic acid molecule comprising a nucleic acid sequence encoding a cell surface molecule that specifically recognizes an antigen, a nucleic acid sequence encoding XCL1, and a nucleic acid sequence encoding Fc. A vector comprising the nucleic acid molecule according to claim 15 .

17. The vector according to claim 16, wherein the vector is selected from the group consisting of a plasmid, a retrovirus, a lentivirus, an adenovirus, a vaccinia virus, a Rous sarcoma virus, a polyoma virus, and an adeno-associated virus.

18. A pharmaceutical composition comprising the engineered cell of any one of claims 1 to 14, the nucleic acid molecule of claim 15 or the vector of claim 16, and one or more pharmaceutically acceptable excipients.

19. Use of the engineered cell of any one of claims 1 to 14, the nucleic acid molecule of claim 15, the vector of claim 16 or the pharmaceutical composition of claim 18 in the preparation of a medicament for treating a subject suffering from cancer, infection or autoimmune disease.

Citation Information

Patent Citations

  • Fusion proteins, and preparation method and application thereof

    CN108623692A

  • Fusion protein comprising CCL3 variant and use thereof cross-reference to related applications

    CN109328194A

  • Engineered immune cell and use thereof

    CN111849910A

  • Tumor nucleic acid vaccine targeting EGFR

    CN113072646A

  • Multispecific prochemokine therapeutic proteins (PARK) and method of making and using thereof

    CN113613727A